About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 293 record(s)
Req # A-2020-001354
Adverse Drug Reactions (ADRs). Report numbers: E2B_02297406, E2B_02310649, E2B_02329607, E2B_02359198, E2B_02359200, E2B_02290951, E2B_02304756, E2B_02310622, E2B_02310639, E2B_02315336, E2B_02356160, E2B_02356162, E2B_02356163, E2B_02362328.Organization: Health Canada
June 2022
Req # A-2021-000302
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-105223-775.Organization: Health Canada
June 2022
Req # A-2021-000343
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-118125-249.Organization: Health Canada
June 2022
Req # A-2021-000761
Adverse Drug Reactions (ADRs). Report numbers: 000948983, E2B_03787485, E2B_03848638, E2B_03817932, E2B_03823366, 000940688, E2B_00744348, E2B_00948569, E2B_03037711, E2B_03175748, E2B_03429750, E2B_03526341, 000951425.Organization: Health Canada
June 2022
Req # A-2021-001027
Adverse Drug Reaction (ADR) for CABAZITAXEL. Report number: E2B_03828775.Organization: Health Canada
June 2022
Req # A-2021-001054
Adverse Drug Reactions (ADRs) for ZOPICLONE. Report numbers: E2B_03840997, E2B_03872642, E2B_03838470, E2B_03789178, E2B_03844156, E2B_03538354, E2B_03530662, E2B_03830553, E2B_03847705, E2B_03848627.Organization: Health Canada
June 2022
Req # A-2021-001070
Adverse Drug Reactions (ADRs). Report numbers: 953276, 000954222, 000955901, 000962471, E2B_04269201, E2B_04269449, E2B_04279409, E2B_04289093, E2B_04289451, E2B_04333419, E2B_04333420, E2B_04344156.Organization: Health Canada
June 2022
Req # A-2021-001084
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-075090-880.Organization: Health Canada
June 2022
Req # A-2021-001091
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-110833-483.Organization: Health Canada
June 2022
Req # A-2021-001147
Adverse Drug Reaction (ADR) for RILUZOLE. Report number: E2B_03720529.Organization: Health Canada
June 2022